Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

To Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03707535
Recruitment Status : Active, not recruiting
First Posted : October 16, 2018
Last Update Posted : August 3, 2020
Sponsor:
Information provided by (Responsible Party):
Celltrion

Brief Summary:
To demonstrate that CT-P13 is equivalent to China-approved Remicade at Week 14, in terms of efficacy as determined by clinical response according to the change from baseline in disease activity.

Condition or disease Intervention/treatment Phase
Rheumatoid Arthritis Biological: CT-P13 Biological: Remicade Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 270 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Controlled, Double-Blind, Phase 3 Study to Compare the Efficacy, Pharmacokinetics and Safety Between CT-P13 and China Approved Remicade When Co-administered With Methotrexate in Patients With Active Rheumatoid Arthritis
Actual Study Start Date : November 12, 2018
Estimated Primary Completion Date : August 21, 2020
Estimated Study Completion Date : June 30, 2021

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: CT-P13 Biological: CT-P13
3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid

Active Comparator: China-approved Remicade Biological: Remicade
3 mg/kg, 2-hour infusion per dose co-administered with methotrexate and folic acid




Primary Outcome Measures :
  1. Efficacy assessment: DAS28 (CRP) at Week 14 [ Time Frame: Week 14 ]
    Clinical response according to the change from baseline in disease activity as measured by the Disease Activity Score using 28 joint counts (DAS28) (C-reactive protein[CRP])



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Has a diagnosis of rheumatoid arthritis
  • Has active disease as defined in DAS28 Criteria

Exclusion Criteria:

  • Has a history of tuberculosis (TB) or a current diagnosis of TB
  • Has previously received a biological agent
  • Has previously received a tumor necrosis factor alpha (TNF α) inhibitor
  • Allergies to any of the excipients of infliximab or hypersensitivity to murine and/or human proteins or immunoglobulin products
  • Pregnant or lactating

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03707535


Locations
Layout table for location information
China
Peking Union Medical College Hospital
Beijing, China, 100730
Sponsors and Collaborators
Celltrion
Layout table for additonal information
Responsible Party: Celltrion
ClinicalTrials.gov Identifier: NCT03707535    
Other Study ID Numbers: CT-P13 3.6
First Posted: October 16, 2018    Key Record Dates
Last Update Posted: August 3, 2020
Last Verified: July 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Arthritis
Arthritis, Rheumatoid
Joint Diseases
Musculoskeletal Diseases
Rheumatic Diseases
Connective Tissue Diseases
Autoimmune Diseases
Immune System Diseases
Infliximab
Dermatologic Agents
Gastrointestinal Agents
Antirheumatic Agents